Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christian Puttinger"'
Autor:
Tobias Welponer, Christian Puttinger, Eva W. H. Korte, Sjoukje van der Werf, Christine Prodinger, Marieke C. Bolling, Martin Laimer
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Introduction Itch is one of the most burdensome symptoms in epidermolysis bullosa (EB), indicating a hitherto unmet therapeutic need. This review leverages existing data on efficacy of itch treatment in EB to support sound decision making.Methods A s
Externí odkaz:
https://doaj.org/article/9ef53977388448e79a451f9347c7bc67
Autor:
Bilal Khalil, Deepak Chhangani, Melissa C. Wren, Courtney L. Smith, Jannifer H. Lee, Xingli Li, Christian Puttinger, Chih-Wei Tsai, Gael Fortin, Dmytro Morderer, Junli Gao, Feilin Liu, Chun Kim Lim, Jingjiao Chen, Ching-Chieh Chou, Cara L. Croft, Amanda M. Gleixner, Christopher J. Donnelly, Todd E. Golde, Leonard Petrucelli, Björn Oskarsson, Dennis W. Dickson, Ke Zhang, James Shorter, Shige H. Yoshimura, Sami J. Barmada, Diego E. Rincon-Limas, Wilfried Rossoll
Publikováno v:
Molecular Neurodegeneration, Vol 17, Iss 1, Pp 1-27 (2022)
Abstract Background Cytoplasmic mislocalization and aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of the amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) disease spectrum, causing both nuclear loss-of-function an
Externí odkaz:
https://doaj.org/article/bbd064334e3c44abbee70cb5d84f3100
Autor:
Tobias Moser, Ciara O’Sullivan, Christian Puttinger, Julia Feige, Georg Pilz, Elisabeth Haschke-Becher, Janne Cadamuro, Hannes Oberkofler, Wolfgang Hitzl, Andrea Harrer, Jörg Kraus, Eugen Trinka, Peter Wipfler
Publikováno v:
Biomedicines, Vol 9, Iss 11, p 1584 (2021)
Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment
Externí odkaz:
https://doaj.org/article/28d8262f759248cb881756d95757c55c
Autor:
Peter Wipfler, Wolfgang Hitzl, Eugen Trinka, Jörg Kraus, Julia Feige, Janne Cadamuro, Georg Pilz, Christian Puttinger, Hannes Oberkofler, Ciara O’Sullivan, Elisabeth Haschke-Becher, Tobias Moser, Andrea Harrer
Publikováno v:
Biomedicines
Biomedicines, Vol 9, Iss 1584, p 1584 (2021)
Volume 9
Issue 11
Biomedicines, Vol 9, Iss 1584, p 1584 (2021)
Volume 9
Issue 11
Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2114822d43b94846322004d2930ae0c6
https://doi.org/10.3390/biomedicines9111584
https://doi.org/10.3390/biomedicines9111584
